Healthcare Industry News: Elekta
News Release - May 28, 2008
TomoTherapy Earns Top Honors in MD Buyline Review of Radiation Therapy VendorsMADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ: TOMO ) today announced that it has earned the top user satisfaction composite rating among four vendors in the linear accelerator-based radiation therapy marketplace. The ratings appear in MD Buyline's Quarterly User Satisfaction Report, which was published on April 15, 2008.
MD Buyline, a leading independent healthcare research company, measures user satisfaction by surveying each vendor’s installed base. Hospitals and cancer centers rank their satisfaction in six areas: system performance; system reliability; installation and implementation; applications training; service response time; and service repair quality.
In MD Buyline-conducted user interviews, customers noted the TomoTherapy® Hi·Art® treatment system’s strengths as its unique design and software, and superiority for intensity-modulated radiation therapy (IMRT). With respect to the company, customers noted: an improvement in overall system reliability; satisfaction with how manufacturer pre-sets and commissioning shorten the installation process; and greater satisfaction in system service.
In rating TomoTherapy, MD Buyline wrote, “TomoTherapy is the only vendor for the CT-based linear accelerator which delivers radiation dose in a helical or fan beam fashion. Elekta, Siemens and Varian offer IMRT and IGRT options on conventional linear accelerator systems.”
Said Fred Robertson, CEO of TomoTherapy: “Our customers expect the best from TomoTherapy because we are the industry innovator and treatment quality leader. The MD Buyline surveys, a resource for more than 3,300 hospitals, indicate that we are meeting expectations. Of course, we know there is more work to be done. On behalf of our customers and their patients, we are committed to continually improving our revolutionary radiation therapy platform."
MD Buyline is a market intelligence organization founded in 1983. It provides the healthcare industry with independent analysis and reporting.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.